Abnova Taiwan Corp (4133) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Abnova Taiwan Corp (4133) has a cash flow conversion efficiency ratio of 0.010x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$12.71 Million ≈ $400.43K USD) by net assets (NT$1.27 Billion ≈ $40.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Abnova Taiwan Corp stock valuation for the company's overall valuation and market capitalisation.
Abnova Taiwan Corp - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Abnova Taiwan Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Abnova Taiwan Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abnova Taiwan Corp ranked by their cash flow conversion efficiency. Explore 4133 cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SIM Acquisition Corp. I Class A Ordinary Shares
NASDAQ:SIMA
|
-0.045x |
|
SANGBO Corp
KQ:027580
|
-0.080x |
|
Hsinjing Holding Co Ltd
TWO:3713
|
0.028x |
|
Jindalee Lithium Ltd
AU:JLL
|
-0.111x |
|
Marka Yatirim Holding AS
IS:MARKA
|
N/A |
|
Electromagnetica SA
RO:ELMA
|
0.031x |
|
Pancontinental Oil & Gas N.L. R
F:PUB
|
-0.017x |
|
TGI Infrastructures Ltd
TA:TGI
|
0.047x |
Annual Cash Flow Conversion Efficiency for Abnova Taiwan Corp (2009–2025)
The table below shows the annual cash flow conversion efficiency of Abnova Taiwan Corp from 2009 to 2025. View Abnova Taiwan Corp (4133) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.26 Billion ≈ $39.59 Million |
NT$-4.19 Million ≈ $-132.07K |
-0.003x | -108.59% |
| 2024-12-31 | NT$1.31 Billion ≈ $41.25 Million |
NT$50.85 Million ≈ $1.60 Million |
0.039x | -34.46% |
| 2023-12-31 | NT$1.29 Billion ≈ $40.53 Million |
NT$76.22 Million ≈ $2.40 Million |
0.059x | -42.17% |
| 2022-12-31 | NT$1.29 Billion ≈ $40.70 Million |
NT$132.37 Million ≈ $4.17 Million |
0.102x | +33.67% |
| 2021-12-31 | NT$1.21 Billion ≈ $38.18 Million |
NT$92.88 Million ≈ $2.93 Million |
0.077x | -11.85% |
| 2020-12-31 | NT$1.21 Billion ≈ $38.16 Million |
NT$105.30 Million ≈ $3.32 Million |
0.087x | +39.14% |
| 2019-12-31 | NT$1.19 Billion ≈ $37.57 Million |
NT$74.51 Million ≈ $2.35 Million |
0.062x | -13.99% |
| 2018-12-31 | NT$1.23 Billion ≈ $38.66 Million |
NT$89.17 Million ≈ $2.81 Million |
0.073x | +31.77% |
| 2017-12-31 | NT$1.22 Billion ≈ $38.59 Million |
NT$67.53 Million ≈ $2.13 Million |
0.055x | -9.84% |
| 2016-12-31 | NT$1.18 Billion ≈ $37.06 Million |
NT$71.94 Million ≈ $2.27 Million |
0.061x | -2.83% |
| 2015-12-31 | NT$1.17 Billion ≈ $36.76 Million |
NT$73.43 Million ≈ $2.31 Million |
0.063x | -17.82% |
| 2014-12-31 | NT$1.23 Billion ≈ $38.74 Million |
NT$94.18 Million ≈ $2.97 Million |
0.077x | -14.21% |
| 2013-12-31 | NT$1.23 Billion ≈ $38.74 Million |
NT$109.78 Million ≈ $3.46 Million |
0.089x | +44.31% |
| 2012-12-31 | NT$1.23 Billion ≈ $38.72 Million |
NT$76.02 Million ≈ $2.40 Million |
0.062x | -41.44% |
| 2011-12-31 | NT$1.27 Billion ≈ $40.03 Million |
NT$134.22 Million ≈ $4.23 Million |
0.106x | +17.26% |
| 2010-12-31 | NT$1.27 Billion ≈ $40.01 Million |
NT$114.40 Million ≈ $3.60 Million |
0.090x | +71.09% |
| 2009-12-31 | NT$1.21 Billion ≈ $38.13 Million |
NT$63.72 Million ≈ $2.01 Million |
0.053x | -- |
About Abnova Taiwan Corp
Abnova (Taiwan) Corporation engages in the research, development, manufacturing, and sales of monoclonal and multiclonal antibodies, proteins, medical diagnostic instruments, and testing reagents. The company's products portfolio includes SARS-CoV/CoV-2, DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems,… Read more